Medicine
More
-
NEW YORK-- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped develop.
-
*Rigel shares slump 33 pct, AstraZeneca little changed. LONDON, April 5- AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain.
-
NEW YORK, April 5- A federal judge on Friday ordered the U.S. Food and Drug Administration to make the "morning-after" emergency contraception pill available without a prescription to all girls of reproductive age.
-
WICHITA, Kan.-- A new clinic offering abortions and other women's medical services saw its first patient Thursday in the Wichita building where a slain Kansas abortion provider had practiced. "We have been working a long time, really hard to get this open to provide services to women in Wichita," said Kerry Townsend Jacob, the group's spokeswoman.
-
TULSA, Okla.-- Oklahoma health officials who discovered unsanitary conditions inside a Tulsa oral surgeon's office said Thursday they will consider medical tests for his patients' spouses and sex partners if lab results show his clinics helped spread hepatitis or the virus that causes AIDS.
-
NEW YORK, April 5- A federal judge on Friday ordered the U.S. Food and Drug Administration to make the "morning-after" emergency contraception pill available to girls of all ages without a prescription.
-
GENEVA, April 5- The World Health Organization said on Friday there was no sign of "sustained human-to-human transmission" of the H7N9 virus in China, but it was important to check on 400 people who had been in close contact with the 14 confirmed cases.
-
LONDON, April 5- AstraZeneca's experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group's few advanced pipeline products uncertain.
-
NEW YORK-- Vertex Pharmaceuticals Inc. said Friday it will work with Bristol-Myers Squibb Co. to study a potential hepatitis C treatment regimen that includes Bristol-Myers Squibb's drug daclatasvir and Vertex's VX-135. Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States.
-
Cancer clinics are turning away thousands of Medicare patients. Dr. Jeff Vacira, North Shore Hematology Oncology chief executive; Eric Schnipper, NRAD Medical Associates; and Howard Dean, (D) former Vermont governor.
-
ATLANTA-- CryoLife Inc. said Thursday that the Food and Drug Administration cleared a new version of its HeRO graft. CryoLife said the new version of the graft has an adaptor that allows physicians to combine the HeRO with other dialysis access grafts. Shares of CryoLife rose 19 cents, or 3.2 percent, to $6.06 in afternoon trading.
-
CAMBRIDGE, Mass.-- Ariad Pharmaceuticals Inc. said Thursday that more than 325 patients have been treated with its drug Iclusig in the three months the leukemia pill has been on the market. Ariad believes European Union regulators will approve Iclusig during the second quarter, and by July 1 it will be prepared to launch the drug in Europe.
-
*China reports 10 cases, four deaths, from new bird flu. And according to Ab Osterhaus, a world leading flu researcher who is head of viroscience of the Erasmus Medical Centre in the Netherlands, studies his team and another in the United States have been doing are the best way to find out.
-
In addition to superbugs' deadly human toll, associated health costs run into the billions. Some warn that we may never win our war against them as research tapers off.
-
*Experts in daily talks on risks posed by new China virus. LONDON, April 4- Experts from around the world are in daily talks about the threat posed by a deadly new strain of bird flu in China, including discussions on if and when to start making a vaccine.
-
*Nine confirmed cases so far in China, three patients dead. But there is no evidence so far that the H7N9 flu- now known to have infected nine people in China, killing three- is spreading from person to person, and there is still a chance it might peter out and never fully mutate into a human form of flu.
-
LONDON, April 3- AstraZeneca boosted its early-stage pipeline of experimental heart drugs on Wednesday by buying privately held U.S. biotechnology company AlphaCore Pharma, which is developing a new type of cholesterol medicine.
-
*Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug. *Analysts expect company to relay FDA feedback in April. April 2- After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.
-
NEW YORK-- Shares of Inovio Pharmaceuticals Inc. skidded Tuesday after the company reported negative data from a clinical trial of an experimental hepatitis C vaccine.
-
Bob and Suzanne Wright, co-founders of Autism Speaks, discuss the organization's efforts to foster research and raise awareness about Autism.